COLL
Collegium Pharmaceutical Inc
21.80$
+0.1%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +9.5% | -3.2% | +0.2% | +9.7% | +14.2% | -2.3% | +5.8% | +11.4% | -1.9% | -5.8% | +3.3% | – | |
| – | -2.3% | -3.0% | +1.9% | +14.8% | +33.8% | -3.9% | -1.0% | +0.7% | -3.9% | -1.0% | +17.5% | – | |
| – | +17.8% | -3.4% | -0.7% | +6.6% | +1.5% | -1.0% | +11.4% | +19.2% | -0.6% | -8.7% | -5.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -27.7% | +64.4% | +3.2% | +43.0% | -22.5% | +59.3% | -3.6% | -8.9% | +0.8% | +27.7% | +23.4% | – | |
| – | -6.7% | +27.4% | +3.2% | +43.0% | -2.9% | +25.7% | -3.1% | -10.5% | +5.5% | +23.3% | +25.0% | – | |
| – | +37.0% | -19.8% | -4.0% | -26.6% | +9.4% | -43.1% | +61.9% | +81.2% | -6.9% | -46.0% | -88.4% | – | |
| – | -7.2% | -10.1% | -10.1% | +18.0% | +23.2% | -8.2% | -1.6% | +6.4% | +381.4% | -84.9% | +23.1% | – | |
| – | +62.3% | -21.6% | -20.5% | -46.5% | +10.8% | -81.9% | +445.3% | +155.1% | -33.2% | -35.5% | -172.2% | – | |
| – | +81.2% | -39.7% | +6.5% | -34.2% | -24.2% | -85.1% | +615.2% | +136.6% | +1.2% | -64.8% | -64.2% | – | |
| – | +54.8% | -13.2% | -29.3% | -52.4% | +34.3% | -80.7% | +395.8% | +162.9% | -46.2% | -14.5% | -203.8% | – | |
| – | +17.1% | -11.9% | -10.3% | -5.5% | +27.4% | -16.5% | +16.9% | +29.3% | +149.4% | -70.2% | -21.9% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.